Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 19/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 15/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368125 | 0.81 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL369148 | 0.80 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL367621 | 0.80 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL5967125 | 0.76 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL13790268 | 0.76 | CYP17A1 (0.73) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL368959 | 0.75 | CYP17A1 (0.58) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL368956 | 0.74 | CYP17A1 (0.74) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL370018 | 0.74 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL16027088 | 0.74 | CYP17A1 (0.59) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL368955 | 0.74 | CYP17A1 (0.57) | CYP17A1CYP1A2CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |